Jeffrey J Hsu1, Ronit Katz2, Joachim H Ix3, Ian H de Boer4, Bryan Kestenbaum4, Michael G Shlipak1. 1. Division of General Internal Medicine, San Francisco VA Medical Center, University of California, San Francisco, CA, USA. 2. Department of Biostatistics, University of Washington, Seattle, WA, USA. 3. Division of Nephrology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA. 4. Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Serum fibroblast growth factor-23 (FGF-23) is associated with cardiovascular disease (CVD), yet the mechanisms remain uncertain. Our objective was to determine whether higher FGF-23 concentrations are associated with arterial stiffness. METHODS: In this cross-sectional study, serum FGF-23 concentrations were measured in 5977 participants without known CVD in the Multi-Ethnic Study of Atherosclerosis. The primary outcomes of interest were large (LAE) and small artery elasticity (SAE), pulse pressure and ankle-brachial index (ABI) > 1.30. LAE and SAE were measured by pulse contour analysis of the radial artery. Pulse pressure was measured with an automated sphygmomanometer using the average of two resting blood pressure measurements. ABI was calculated as the ratio of the ankle and brachial systolic blood pressures. RESULTS: Serum FGF-23 concentrations were not significantly associated with LAE [relative difference (RD) per doubling: 0%; 95% confidence interval (CI): -2-1%], SAE (RD per doubling: 0%; 95% CI: -3-2%), pulse pressure (β per doubling: 0.44; 95% CI: -0.31-1.19), or a high ABI (odds ratio per doubling: 1.14; 95% CI: 0.84-1.55). Findings were similar irrespective of chronic kidney disease status. CONCLUSIONS: Higher serum FGF-23 concentrations are not associated with arterial stiffness, as measured by pulse pressure, LAE, SAE or high ABI, in a community-based population without CVD. Published by Oxford University Press on behalf of ERA-EDTA 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Serum fibroblast growth factor-23 (FGF-23) is associated with cardiovascular disease (CVD), yet the mechanisms remain uncertain. Our objective was to determine whether higher FGF-23 concentrations are associated with arterial stiffness. METHODS: In this cross-sectional study, serum FGF-23 concentrations were measured in 5977 participants without known CVD in the Multi-Ethnic Study of Atherosclerosis. The primary outcomes of interest were large (LAE) and small artery elasticity (SAE), pulse pressure and ankle-brachial index (ABI) > 1.30. LAE and SAE were measured by pulse contour analysis of the radial artery. Pulse pressure was measured with an automated sphygmomanometer using the average of two resting blood pressure measurements. ABI was calculated as the ratio of the ankle and brachial systolic blood pressures. RESULTS: Serum FGF-23 concentrations were not significantly associated with LAE [relative difference (RD) per doubling: 0%; 95% confidence interval (CI): -2-1%], SAE (RD per doubling: 0%; 95% CI: -3-2%), pulse pressure (β per doubling: 0.44; 95% CI: -0.31-1.19), or a high ABI (odds ratio per doubling: 1.14; 95% CI: 0.84-1.55). Findings were similar irrespective of chronic kidney disease status. CONCLUSIONS: Higher serum FGF-23 concentrations are not associated with arterial stiffness, as measured by pulse pressure, LAE, SAE or high ABI, in a community-based population without CVD. Published by Oxford University Press on behalf of ERA-EDTA 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf Journal: J Clin Invest Date: 2011-10-10 Impact factor: 14.808
Authors: Mohamed M Nasrallah; Amal R El-Shehaby; Mona M Salem; Noha A Osman; Esam El Sheikh; Usama A A Sharaf El Din Journal: Nephrol Dial Transplant Date: 2010-02-22 Impact factor: 5.992
Authors: Carmen A Peralta; David R Jacobs; Ronit Katz; Joachim H Ix; Magdalena Madero; Daniel A Duprez; Mark J Sarnak; Michael H Criqui; Holly J Kramer; Walter Palmas; David Herrington; Michael G Shlipak Journal: Am J Kidney Dis Date: 2011-10-14 Impact factor: 8.860
Authors: Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix Journal: Ann Intern Med Date: 2010-05-18 Impact factor: 25.391
Authors: Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf Journal: JAMA Date: 2011-06-15 Impact factor: 56.272
Authors: Daniel A Duprez; David R Jacobs; Pamela L Lutsey; David A Bluemke; Lyndia C Brumback; Joseph F Polak; Carmen A Peralta; Philip Greenland; Richard A Kronmal Journal: Am J Epidemiol Date: 2011-06-27 Impact factor: 4.897
Authors: Michael H Criqui; Robyn L McClelland; Mary M McDermott; Matthew A Allison; Roger S Blumenthal; Victor Aboyans; Joachim H Ix; Gregory L Burke; Kaing Liu; Steven Shea Journal: J Am Coll Cardiol Date: 2010-10-26 Impact factor: 24.094
Authors: Carmen A Peralta; Kathryn L Adeney; Michael G Shlipak; David Jacobs; Daniel Duprez; David Bluemke; Joseph Polak; Bruce Psaty; Bryan R Kestenbaum Journal: Am J Epidemiol Date: 2009-11-30 Impact factor: 4.897
Authors: Barry I Freedman; Jasmin Divers; Gregory B Russell; Nicholette D Palmer; Donald W Bowden; J Jeffrey Carr; Lynne E Wagenknecht; R Caresse Hightower; Jianzhao Xu; Susan Carrie Smith; Carl D Langefeld; Keith A Hruska; Thomas C Register Journal: Am J Nephrol Date: 2015-12-23 Impact factor: 3.754
Authors: Nicole M Lioufas; Elaine M Pascoe; Carmel M Hawley; Grahame J Elder; Sunil V Badve; Geoffrey A Block; David W Johnson; Nigel D Toussaint Journal: J Am Soc Nephrol Date: 2021-10-13 Impact factor: 10.121
Authors: Nigel D Toussaint; Eugenia Pedagogos; Nicole M Lioufas; Grahame J Elder; Elaine M Pascoe; Sunil V Badve; Andrea Valks; Geoffrey A Block; Neil Boudville; James D Cameron; Katrina L Campbell; Sylvia S M Chen; Randall J Faull; Stephen G Holt; Dana Jackson; Meg J Jardine; David W Johnson; Peter G Kerr; Kenneth K Lau; Lai-Seong Hooi; Om Narayan; Vlado Perkovic; Kevan R Polkinghorne; Carol A Pollock; Donna Reidlinger; Laura Robison; Edward R Smith; Robert J Walker; Angela Yee Moon Wang; Carmel M Hawley Journal: J Am Soc Nephrol Date: 2020-09-11 Impact factor: 10.121
Authors: Emma A Vermeulen; Coby Eelderink; Tiny Hoekstra; Adriana J van Ballegooijen; Pieter Raijmakers; Joline W Beulens; Martin H de Borst; Marc G Vervloet Journal: Trials Date: 2022-09-12 Impact factor: 2.728
Authors: Gary C Chan; Jasmin Divers; Gregory B Russell; Carl D Langefeld; Lynne E Wagenknecht; Fang-Chi Hsu; Jianzhao Xu; S Carrie Smith; Nicholette D Palmer; Pamela J Hicks; Donald W Bowden; Thomas C Register; Lijun Ma; J Jeffrey Carr; Barry I Freedman Journal: Diabetes Care Date: 2017-11-07 Impact factor: 19.112